Publication | Closed Access
Continuous Insulin Infusion in Hyperglycemic, Very Low Birth Weight Infants
62
Citations
0
References
1982
Year
NutritionNeonatologyObesityMetabolic SyndromeIntravenous Glucose ToleranceBody CompositionContinuous Insulin InfusionInsulin DeliveryHealth SciencesDiabetes ManagementInsulin ManagementMaternal HealthGestational DiabetesNewborn MedicineInsulin InfusionDiabetesInfant NutritionPediatricsPhysiologyBlood Glucose MonitoringDiabetes MellitusHyperglycemiaMetabolismMedicine
Continuous insulin infusion (CII) was used to increase intravenous glucose tolerance in 10 extremely premature (26.2 +/- 0.04 weeks, means +/- SEM) very low birth weight (819 +/- 53 g) hyperglycemic infants. CII was continued for 3-36 days. Over the first 72 h of insulin administration the mean amount of glucose tolerated rose from 0.35 +/- 0.06 to 0.67 +/- 0.06 g/kg/h and caloric intake derived from intravenous glucose increased from 29 to 56 kcal/kg/day. Insulin doses required to maintain normoglycemia ranged from 0.005-0.052 U/kg/h initially to 0.002-0.086 U/kg/h after 72 h of CII. Plasma insulin levels were significantly higher during insulin infusion. The low insulin doses required to maintain normoglycemia were consistent with a state of relative insulin deficiency, rather than insulin resistance. Mean plasma insulin/glucose ratios were significantly higher in normoglycemic versus hyperglycemic infants (0.40 +/- 0.08 vs. 0.14 +/- 0.05). Less than 1% of all blood glucose estimations were less than 25 mg/dl. Seventy-eight percent were within the normal range (greater than 45, less than 130 mg/dl). The rate of weight gain increased during CII in 8 of the 10 infants. CII may be useful in extremely premature, very-low-birth-weight infants in whom glucose intolerance persists despite conservative treatment, and either severely limits caloric intake, or results in life-threatening hyperglycemia.